TW200611695A - Pyrrolopyridine derivatives - Google Patents

Pyrrolopyridine derivatives

Info

Publication number
TW200611695A
TW200611695A TW094118669A TW94118669A TW200611695A TW 200611695 A TW200611695 A TW 200611695A TW 094118669 A TW094118669 A TW 094118669A TW 94118669 A TW94118669 A TW 94118669A TW 200611695 A TW200611695 A TW 200611695A
Authority
TW
Taiwan
Prior art keywords
pyrrolopyridine derivatives
diseases
derivatives
indirectly
decrease
Prior art date
Application number
TW094118669A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew John Eatherton
Gerard Martin Paul Giblin
Matthew Russell Johnson
William Leonard Mitchell
Alcide Perboni
Brian Peter Slingsby
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412908A external-priority patent/GB0412908D0/en
Priority claimed from GB0424950A external-priority patent/GB0424950D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TW200611695A publication Critical patent/TW200611695A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW094118669A 2004-06-09 2005-06-07 Pyrrolopyridine derivatives TW200611695A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0412908A GB0412908D0 (en) 2004-06-09 2004-06-09 Compounds
GB0424950A GB0424950D0 (en) 2004-11-11 2004-11-11 Compounds

Publications (1)

Publication Number Publication Date
TW200611695A true TW200611695A (en) 2006-04-16

Family

ID=34969264

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094118669A TW200611695A (en) 2004-06-09 2005-06-07 Pyrrolopyridine derivatives

Country Status (25)

Country Link
US (1) US7589206B2 (https=)
EP (1) EP1753764B1 (https=)
JP (1) JP2008501758A (https=)
KR (1) KR20070034049A (https=)
AR (1) AR050158A1 (https=)
AT (1) ATE412651T1 (https=)
AU (1) AU2005251913A1 (https=)
BR (1) BRPI0511874A (https=)
CA (1) CA2569887A1 (https=)
DE (1) DE602005010698D1 (https=)
DK (1) DK1753764T3 (https=)
ES (1) ES2317244T3 (https=)
HR (1) HRP20090034T3 (https=)
IL (1) IL179603A0 (https=)
MA (1) MA28686B1 (https=)
MX (1) MXPA06014471A (https=)
NO (1) NO20070067L (https=)
PE (1) PE20060430A1 (https=)
PL (1) PL1753764T3 (https=)
PT (1) PT1753764E (https=)
RU (1) RU2006147278A (https=)
SI (1) SI1753764T1 (https=)
TW (1) TW200611695A (https=)
UY (1) UY28945A1 (https=)
WO (1) WO2005121140A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
KR20070034049A (ko) 2004-06-09 2007-03-27 글락소 그룹 리미티드 피롤로피리딘 유도체
KR101764575B1 (ko) † 2004-07-28 2017-08-03 다케다 야쿠힌 고교 가부시키가이샤 피롤로〔2,3-ｃ〕피리딘 화합물, 그 제조 방법 및 용도
KR100958829B1 (ko) * 2004-09-03 2010-05-25 주식회사유한양행 피롤로[2,3-ｃ]피리딘 유도체 및 그의 제조방법
GB0516379D0 (en) * 2005-08-09 2005-09-14 Glaxo Group Ltd Compounds
WO2007017237A1 (en) * 2005-08-09 2007-02-15 Glaxo Group Limited Imidazopyridine derivatives as cannabinoid receptor ligands
US20090275611A1 (en) * 2006-04-07 2009-11-05 Boehringer Ingelheim International Gmbh Compounds Which Modulate The CB2 Receptor
US20100041672A1 (en) * 2007-03-21 2010-02-18 Glaxo Group Limited Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
AU2010231694A1 (en) 2009-03-30 2011-10-06 Astellas Pharma Inc. Pyrimidine compound
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
RS55186B1 (sr) * 2010-07-29 2017-01-31 Astellas Pharma Inc Kondenzovana jedinjenja piridina kao ligandi cb2 kanabinoidnog receptora
JP6326563B2 (ja) * 2012-03-19 2018-05-23 アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド β−カリオフィレンとＣＢ２受容体アゴニストを用いた精神病の治療
WO2014210255A1 (en) 2013-06-26 2014-12-31 Abbvie Inc. Primary carboxamides as btk inhibitors
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
CA3120866A1 (en) * 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US11858935B1 (en) 2023-09-06 2024-01-02 King Faisal University Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors
US11891394B1 (en) 2023-09-06 2024-02-06 King Faisal University Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113245B1 (en) * 1982-12-29 1989-03-15 Kureha Kagaku Kogyo Kabushiki Kaisha Cephalosporin derivatives
CA2031927A1 (en) 1989-12-27 1991-06-28 Imperial Oil Limited Method for improving the activity maintenance of a plasma initiator
WO1991009598A1 (en) 1990-01-05 1991-07-11 Pfizer Inc. Azaoxindole derivatives
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
GB9109246D0 (en) 1991-04-30 1991-06-19 Ici Plc Nitrogen derivatives
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW263504B (https=) 1991-10-03 1995-11-21 Pfizer
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5468757A (en) 1994-01-31 1995-11-21 Eli Lilly And Company 6-azaindole thromboxane synthase inhibitors
CO4340691A1 (es) 1994-02-18 1996-07-30 Boehringer Ingelheim Pharma 2-HETEROARIL-5,11-DIHIDRO-6H-DIPIRIDO(3,2-b:2´, 3´ -e) (1, 4)-DIAZEPINAS .
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
JPH0920779A (ja) 1995-05-01 1997-01-21 Japan Tobacco Inc 縮合ヘテロ５員環アゼピン化合物類及びその医薬用途
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
WO1998006703A1 (en) 1996-08-14 1998-02-19 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
JP2002511852A (ja) 1997-05-07 2002-04-16 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
EP0931872B1 (de) 1998-01-23 2003-04-09 Voith Paper Patent GmbH Verfahren zur Entfernung von feinen Verunreinigungen aus einer Faserstoffsuspension
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
JP2002523455A (ja) 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体
GB9904995D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
JP2002538206A (ja) 1999-03-10 2002-11-12 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物
CA2367121A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
JP2002538204A (ja) 1999-03-10 2002-11-12 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物
EP1161431A4 (en) 1999-03-10 2002-04-24 Merck & Co Inc 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASE HORMONES
EP1171125A1 (en) 1999-03-10 2002-01-16 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
AU3514200A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
CA2390948A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
CA2407677A1 (en) 2000-04-28 2002-10-28 Baxter Healthcare Sa 2-acyl indol derivatives and their use as anti-tumour agents
AR028385A1 (es) 2000-04-28 2003-05-07 Acadia Pharm Inc Agonistas muscarinicos
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
HK1052705B (en) 2000-08-14 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US6369032B1 (en) 2000-09-06 2002-04-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating allergies
PT1315492E (pt) 2000-09-06 2008-10-01 Ortho Mcneil Pharm Inc Utilização de pirazoles substituídos para o tratamento de alergias
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
IL156776A0 (en) 2001-01-17 2004-02-08 Amura Therapeutics Ltd Inhibitors of cruzipain and other cysteine proteases
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
EP1363705B9 (en) 2001-02-02 2012-11-07 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
ES2278016T3 (es) 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
CN1527710A (zh) 2001-05-14 2004-09-08 ����˹�ж�-����˹˹����ҩƷ��˾ 作为促肾上腺皮质激素释放因子配体的取代的吡嗪酮、吡啶和嘧啶
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
DE10143079A1 (de) 2001-09-03 2003-05-15 Zentaris Ag Cyclische Indol- und Heteroindolderivate, deren Herstellung und Verwendung als Arzneimittel
WO2003022214A2 (en) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
JP2005508968A (ja) 2001-10-19 2005-04-07 トランス　テック　ファーマ，インコーポレイテッド ＰＴＰ阻害剤としてのβ−カルボリン誘導体
DE10152306A1 (de) 2001-10-26 2003-07-24 Asta Medica Ag 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
TW200301251A (en) 2001-12-20 2003-07-01 Wyeth Corp Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
WO2003080608A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline and aza-indole derivatives and their use as 5-ht6 ligands
WO2003087087A2 (en) 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US20040063744A1 (en) 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
US6900206B2 (en) 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
DE60304718T2 (de) 2002-08-06 2007-04-26 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
US20060247261A1 (en) 2002-08-21 2006-11-02 Eatherton Andrew J Pyrimidine compounds
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
EP1572097A4 (en) 2002-09-30 2010-02-17 Smithkline Beecham Corp NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS
FR2845388B1 (fr) 2002-10-08 2004-11-12 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2]nonanecarboxamides, leur preparation et leur application en therapeutique
WO2004074286A1 (en) 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
KR20070034049A (ko) 2004-06-09 2007-03-27 글락소 그룹 리미티드 피롤로피리딘 유도체

Also Published As

Publication number Publication date
DE602005010698D1 (de) 2008-12-11
RU2006147278A (ru) 2008-07-20
PT1753764E (pt) 2009-01-28
DK1753764T3 (da) 2009-02-16
AU2005251913A1 (en) 2005-12-22
IL179603A0 (en) 2007-05-15
ES2317244T3 (es) 2009-04-16
EP1753764A1 (en) 2007-02-21
MA28686B1 (fr) 2007-06-01
UY28945A1 (es) 2006-01-31
BRPI0511874A (pt) 2008-01-15
US7589206B2 (en) 2009-09-15
MXPA06014471A (es) 2007-03-21
HRP20090034T3 (en) 2009-03-31
EP1753764B1 (en) 2008-10-29
SI1753764T1 (sl) 2009-02-28
AR050158A1 (es) 2006-10-04
NO20070067L (no) 2007-02-09
ATE412651T1 (de) 2008-11-15
WO2005121140A1 (en) 2005-12-22
HK1104175A1 (en) 2008-01-04
KR20070034049A (ko) 2007-03-27
JP2008501758A (ja) 2008-01-24
PE20060430A1 (es) 2006-05-25
PL1753764T3 (pl) 2009-04-30
US20070219229A1 (en) 2007-09-20
CA2569887A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
GB0222495D0 (en) Compounds
UA83194C2 (ru) Производные пиримидина и их применение как модуляторов св2
TW200611695A (en) Pyrrolopyridine derivatives
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
GEP20125565B (en) Lactam compounds and their pharmaceutical use
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
NO20063787L (no) Terapeutiske preparater
TW200608960A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
ATE520668T1 (de) Sigmarezeptor-inhibitoren
TW200608966A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
UA83917C2 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
AU2003260436A1 (en) Pyrimidine compounds
TW200734323A (en) 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
TW200745122A (en) New compounds I
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
TW200734335A (en) Compounds
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments